Biodesix (BDSX) Liabilities and Shareholders Equity (2019 - 2026)

Biodesix has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $94.6 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 9.74% year-over-year to $94.6 million; the trailing twelve-month figure through Mar 2026 stood at $358.6 million (down 10.82% YoY), and the FY2025 full-year result was $87.5 million, down 10.04% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $94.6 million, up from $87.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $115.8 million in Q2 2024, with the low at $61.7 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $87.4 million across 5 years, with a median of $87.5 million in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 46.62% — and 2024, when it surged 49.24%.
• Biodesix's Liabilities and Shareholders Equity stood at $92.9 million in 2022, then rose by 6.66% to $99.1 million in 2023, then slipped by 1.87% to $97.2 million in 2024, then retreated by 10.04% to $87.5 million in 2025, then climbed by 8.19% to $94.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $94.6 million (Q1 2026), $87.5 million (Q4 2025), and $88.7 million (Q3 2025), per Business Quant data.